Commentary on recent therapeutic guidelines for osteoarthritis

Area of Science:

• Rheumatology
• Osteoarthritis Management
• Clinical Guidelines

Background:

• International evidence-based guidelines for osteoarthritis (OA) management exist, yet consensus on treatment modalities remains elusive.
• Discrepancies in OA management guidelines may stem from differing expert panels, geographical variations in drug availability, and study heterogeneity.

Purpose of the Study:

• To compare international guidelines and reach a consensus on knee osteoarthritis (OA) management.
• To address areas lacking clear consensus, including non-pharmacological therapy, analgesics, NSAIDs, intra-articular hyaluronates (HA), and chondroitin sulfate (CS)/glucosamine sulfate (GS).

Main Methods:

• A symposium of European and US OA experts convened during the Annual European Congress of Rheumatology.
• Guidelines and recommendations for knee OA treatment were discussed and compared to achieve consensus.

Main Results:

• Experts agreed that knee OA requires both non-pharmacological and pharmacological treatments.
• Guideline implementation can be hindered by drug availability, reimbursement policies, and primary care provider adherence, particularly for non-pharmacological OA treatments.
• Geographical variations significantly impact the availability and prescription of treatments like HA and symptomatic slow-acting drugs for osteoarthritis (SySADOAs).

Conclusions:

• Harmonizing knee OA treatment recommendations is challenging but feasible, as demonstrated by a developed therapeutic algorithm.
• Disseminating and implementing clear OA treatment guidance in primary care settings is essential for improving OA management.